Impact of Treatment Response to Anticoagulant Therapy on Liver‐Related Events in Patients With Cirrhosis and Portal Vein Thrombosis
Open Access
- 24 March 2026
- journal article
- research article
- Published by Wiley in Hepatology Research
- Vol. 56 (7) , 1152-1160
Abstract
Aim: The effect of treatment response to anticoagulant therapy on prognosis of patients with cirrhosis and portal vein thrombosis (PVT) remains unclear. Methods: Forty‐one patients with cirrhosis and first PVT treated with intravenous anticoagulant therapy between January 2015 and April 2018 at 10 Japanese hospitals were included. Treatment response was defined based on change in size of PVT after anticoagulant therapy as the following: complete response (CR, 0%), partial response (PR, ≤ 50%), stable disease (SD, 51%–100%), and progressive disease (PD, ≥ 101%). CR and PR were combined as the effective group and SD and PD formed as the ineffective group. Results: The median age was 69 years, and 56% of the patients had Child–Pugh class B. Overall, 5 (12%) achieved CR, 22 (54%) achieved PR, 12 (29%) had SD and 2 (5%) had PD. During a median follow‐up of 31.8 months from the date of assessment of treatment response, 17 patients died. The overall survival rates at 1‐ and 3‐year were 82.5% and 65.1%, respectively. In the multivariate analysis, the model for end‐stage liver disease‐Na score was significantly associated with overall survival, whereas treatment response was not significant. Twenty‐five patients experienced liver‐related events with hospitalization, and the 3‐year cumulative rate of liver‐related events was 63.9%. In the multivariate analysis, treatment response was significantly associated with liver‐related events. The 3‐year cumulative rates of liver‐related events were 56.7% and 75.5% in the effective and ineffective groups, respectively ( p = 0.008). Conclusions: Among patients with cirrhosis, treatment response to anticoagulant therapy for PVT correlated with the incidence of liver‐related hospitalization events.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP23fk0210121)
This publication has 16 references indexed in Scilit:
- Clinical outcomes of antithrombin III‐based therapy for patients with portal vein thrombosis: A retrospective, multicenter studyHepatology Research, 2022
- Prognosis of patients with liver cirrhosis: A multi‐center retrospective observational studyHepatology Research, 2021
- Evidence‐based clinical practice guidelines for liver cirrhosis 2020Hepatology Research, 2021
- Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysisGastroenterology, 2017
- Antithrombin III for portal vein thrombosis in patients with liver disease: A randomized, double‐blind, controlled trialHepatology Research, 2017
- De-novo portal vein thrombosis in liver cirrhosisEuropean Journal of Gastroenterology & Hepatology, 2015
- Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: Results of a longitudinal studyHepatology, 2015
- Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis developmentJournal of Hepatology, 2009
- Hyponatremia and Mortality among Patients on the Liver-Transplant Waiting ListNew England Journal of Medicine, 2008
- Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studiesJournal of Hepatology, 2006